New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2013
08:31 EDTSNTISenesco announces completion of cohort 3 in Phase 1b/2a SNS01-T trial
Senesco Technologies reported the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple myeloma and lymphoma. The company has also received approval from its Data Review Committee to proceed to cohort 4, which is expected to require six evaluable patients. The Data Review Committee’s review of the results of cohort 3 concluded that SNS01-T was safe and well tolerated at a dose of 0.2 mg/Kg. No drug-related serious adverse events or dose limiting toxicities have been observed in the study. The patients in cohort 4 will be receiving 0.375 mg/Kg of SNS01-T. The study is an open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 relapsed or refractory multiple myeloma, mantle cell or diffuse large B-cell lymphoma patients. While the primary objective is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of monoclonal protein in multiple myeloma and CT imaging in B-cell lymphomas.
News For SNTI From The Last 14 Days
Check below for free stories on SNTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SNTI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use